Profile data is unavailable for this security.
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
- Revenue in USD (TTM)43.29bn
- Net income in USD6.83bn
- Incorporated1994
- Employees95.44k
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Amunix Pharmaceuticals Inc | -6.02% | 1.25bn |
| American Finance Trust Inc-Office Building(3) | -6.01% | 261.00m |
| ORIGIMM Biotechnology GmbH | -2.61% | -- |
| Kadmon Holdings Inc | -6.07% | 1.76bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 23.00bn | 14.06bn | 66.95bn | 2.70k | 5.31 | 3.80 | 4.75 | 2.96 | 32.80 | 32.80 | 53.79 | 45.88 | 1.09 | 3.18 | 9.76 | 8,516,667.00 | 66.62 | 41.17 | 105.90 | 66.78 | 82.29 | -- | 61.12 | 52.35 | 1.71 | -- | 0.0407 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| Regeneron Pharmaceuticals Inc | 14.23bn | 5.69bn | 67.82bn | 10.37k | 12.81 | 3.40 | 11.69 | 4.92 | 50.07 | 50.07 | 125.24 | 188.93 | 0.5844 | 1.02 | 2.34 | 1,372,184.00 | 23.36 | 25.64 | 27.13 | 29.99 | 84.97 | 88.51 | 39.97 | 39.11 | 4.39 | 11.87 | 0.1155 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Vertex Pharmaceuticals Incorporated | 8.35bn | 3.19bn | 76.64bn | 3.90k | 23.92 | 6.35 | 22.76 | 9.08 | 12.37 | 12.37 | 32.33 | 46.61 | 0.6007 | 2.88 | 7.38 | 2,141,135.00 | 22.98 | 18.01 | 27.29 | 21.87 | 88.13 | 87.77 | 38.26 | 29.17 | 4.36 | 28.00 | 0.0389 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Gilead Sciences, Inc. | 27.52bn | 4.14bn | 77.71bn | 14.40k | 19.25 | 3.91 | 12.73 | 2.88 | 3.28 | 3.28 | 21.81 | 16.14 | 0.4206 | 4.11 | 6.66 | 1,910,764.00 | 6.28 | 8.35 | 7.37 | 10.02 | 75.59 | 79.56 | 14.93 | 22.22 | 1.27 | 6.69 | 0.5646 | 58.76 | 10.60 | -2.12 | 4,960.98 | -14.34 | -4.99 | 9.07 |
| Zoetis Inc | 8.00bn | 2.09bn | 79.37bn | 12.10k | 39.50 | 17.81 | 32.00 | 10.19 | 4.41 | 4.41 | 16.85 | 9.77 | 0.5744 | 1.18 | 6.50 | 660,743.80 | 15.00 | 13.79 | 18.40 | 16.04 | 70.44 | 68.75 | 26.12 | 23.94 | 1.46 | 11.64 | 0.5894 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Sanofi SA (ADR) | 43.29bn | 6.83bn | 123.38bn | 95.44k | 16.65 | 1.55 | 13.17 | 2.62 | 2.71 | 2.71 | 17.25 | 29.18 | 0.3591 | 1.38 | 5.73 | 453,546.80 | 5.68 | 5.19 | 6.91 | 6.23 | 69.45 | 68.06 | 15.82 | 15.36 | 0.861 | 32.43 | 0.2311 | -- | 4.83 | 2.46 | -49.38 | 7.20 | -0.387 | -- |
| Amgen, Inc. | 26.38bn | 6.58bn | 132.86bn | 24.20k | 21.36 | 55.74 | 13.56 | 5.11 | 11.80 | 11.80 | 47.50 | 4.52 | 0.4432 | 1.48 | 5.38 | 1,090,248.00 | 11.05 | 11.07 | 14.32 | 13.40 | 75.75 | 79.29 | 24.92 | 30.88 | 1.17 | 7.46 | 0.9379 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 47.14bn | 6.62bn | 160.06bn | 32.20k | 24.88 | 4.90 | 9.34 | 3.39 | 3.01 | 3.01 | 21.49 | 15.27 | 0.4465 | 4.58 | 6.00 | 1,464,099.00 | 6.29 | 2.67 | 7.76 | 3.29 | 79.22 | 74.18 | 14.08 | 6.54 | 1.34 | 5.55 | 0.5629 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 30 Jun 2022 | 77.00m | 3.04% |
| Fisher Asset Management LLCas of 30 Jun 2022 | 17.61m | 0.70% |
| Boston Partners Global Investors, Inc.as of 30 Jun 2022 | 11.90m | 0.47% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 10.13m | 0.40% |
| Managed Account Advisors LLCas of 30 Jun 2022 | 9.46m | 0.37% |
| BlackRock Investment Management LLCas of 30 Jun 2022 | 7.19m | 0.28% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2022 | 6.56m | 0.26% |
| Strategic Advisers LLCas of 30 Jun 2022 | 6.36m | 0.25% |
| Invesco Advisers, Inc.as of 31 Mar 2022 | 4.32m | 0.17% |
| Camber Capital Management LPas of 31 Mar 2022 | 4.00m | 0.16% |
